Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
11 May 2022
CollaborateAntibody
NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- biOasis INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has entered into a research collaboration and license agreement with Neuramedy Co Ltd (“Neuramedy”) of Seoul, Korea.
Neuramedy is a biotech company researching and developing innovative solutions for neurodegenerative diseases. The company aims to provide disease modifying treatments for Parkinson’s disease and other synuclein related diseases.
Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2. Tomaralimab is currently in development for the treatment of Parkinson’s disease and Multiple System Atrophy.
Bioasis will receive an upfront payment and may receive an additional US$72 million in milestone payments and a royalty on net sales.
“We are excited to have entered into this agreement with Bioasis. We expect the xB3TM platform will improve the efficacy and safety of our Tomaralimab. Through the collaboration with the companies like Bioasis, we hope to provide solutions that can improve the lives of patients with neurodegenerative disorders,” said Seung Jae Lee, Ph. D., Neuramedy’s CEO.
“We are very pleased to have entered into this agreement and excited to be working with Neuramedy on this new target for Parkinson’s disease and Alzheimer’s disease. Forming innovative partnerships with companies such as Neuramedy is an important part of our strategy to see the broadest possible uptake of promising technology. Our xB3TM BBB drug delivery platform has the potential to significantly advance the treatment of neurogenerative diseases, solving a major unmet clinical need and improving the lives of patients, said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair.
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3TM platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for certain brain cancers and rare diseases, including Gaucher’s Disease Type II, neurodegenerative diseases including Parkinson’s disease and Lewy Body Dementia and neuroinflammatory conditions including pain, epilepsy and Multiple Sclerosis. Bioasis trades on the TSX Venture Exchange under the symbol “BTI.V” and on the OTCQB under the symbol “BIOAF” For more information about the Company, please visit www.bioasis.us.
About Neuramedy
Neuramedy Co., Ltd. Is a Korean biopharmaceutical company established in 2019 based on the long time research of Dr. Seung Jae Lee. The company envisions the development of disease modifying therapies for early intervention of diseases. The company focuses on developing the treatments for neurodegenerative diseases. The lead pipeline NM-101, Tomaralimab for Parkinson’s disease, is currently in IND preparation. For more information about the company, please visit www.neuramedy.com.<br>
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.